Patent intelligence · US
US 12415861
Anti C-MET antibodies
Anti C-MET antibodies
Patent details — US 12415861
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 16, 2025
- Expiration
- Sep 11, 2045
- Applicant
- CENTESSA PHARMACEUTICALS (UK) LIMITED
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K45/06
Quick answer
US 12415861 (Anti C-MET antibodies) is held by CENTESSA PHARMACEUTICALS (UK) LIMITED. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CENTESSA PHARMACEUTICALS (UK) LIMITED
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K39/39558, A61K45/06
More from CENTESSA PHARMACEUTICALS (UK) LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12421310
CD47 binding agents
granted -
US 12365672
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12291507
Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
granted -
US 12286402
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12227580
Antigen binding molecules that bind LIGHT
granted -
US 12221422
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted
Frequently asked questions
What is US patent 12415861?
US 12415861 (Anti C-MET antibodies) is held by CENTESSA PHARMACEUTICALS (UK) LIMITED. Status: granted. Granted Sep 16, 2025. Expires Sep 11, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12415861?
CENTESSA PHARMACEUTICALS (UK) LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12415861 expire?
Our index shows an expiration date of Sep 11, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.